A new anti-allergic drug, ICI 74.917 aerosol.
Ten hay fever patients were challenged intranasally with allergen before, half an hour, 2 hours and 4 hours after intranasal use of disodium cromoglycate powder, placebo and ICI 74.917, a new serosoled compound with anti-allergic action. The new compound showed a maximum protective effect after half an hour, and a significant difference was found also after 2 hours, and a significant difference was found also after 2 hours. The effect was also significantly better than that of disodium cromoglycate powder. The results were positive enough to make further human studies of ICI 74.917 desirable.
D000336:Aerosols; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D010618:Phenanthrolines / Q000008:administration & dosage / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D013997:Time Factors
D000336:Aerosols; D010618:Phenanthrolines; D004205:Cromolyn Sodium